The planned program is part of beta test of Repositive’s Cancer Models platform which connects biopharmaceutical companies and contract research organizations.
The senior unsecured term loan facility was used, in part, to refinance a three-year loan agreement between BD, Citibank, and other lenders reached last year.
The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.
The test is a targeted sequencing assay that detects mutations in the blood of non-small cell lung cancer patients to inform treatment selection.
The firm plans to use the funds to develop a five-minute point-of-care molecular diagnostic system for multiplexed infectious disease detection.
Under the deal, Novacyt's Primerdesign business will work with Applied Microarrays on the development of microarray-based diagnostic assays.
The CPMC study aims to provide participants with their genetic and non-genetic risks for disease and drug response and monitor how their behaviors change.
Arbor will provide reagents to Tataa for its courses on next-generation sequencing applications, while Tataa will distribute Arbor's products in European countries.
The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.
The firm will sell more than 14 million shares of its common stock for $4.25 per share.
Premier is a healthcare group purchasing organization representing about 4,000 hospitals and 165,000 other providers throughout the US.
The companies initially expect to incorporate a CDx for Incyte's pemigatinib into Foundation Medicine's existing FDA-approved assay, FoundationOne CDx.
The firm did not disclose how many shares it planned to sell or how much money it expects to raise.
Expedeon's colloidal gold is an aqueous suspension of uniform, spherical metallic nanoparticles that can conjugate to antibodies and antigens.
The court upheld a judgement of no interference-in-fact from the Patent Trial and Appeal Board, leaving the Broad in control of key CRISPR IP.
CHOP's Gabriella Miller Kids First Pediatric Data Resource Center will use PhenoTips software from Gene42 to integrate "deep phenotyping" with genomic data.
Merck will use Definiens' web-based collaboration software platform alongside Definiens' image-analysis technologies for biomarker quantification.
After an unsuccessful commercialization attempt more than a decade ago, the company is bringing a revamped version of the ion mobility technology to market.
The assay will combine the company's CytoSort assay with its automated AIR system for imaging, sorting, and isolating single cells and small colonies.
The companies will combine GenomOncology's GO Immuno-Oncology Workbench analysis software with Fluidigm's Advanta IO Gene Expression Assay.
An Australian-led team has generated a draft genome assembly of the invasive cane toad in hopes it will help in population control, the Sydney Morning Herald reports.
The New York Times reports that the US Department of Defense has implemented about half the recommendations made to improve safe handling of dangerous agents.
In PLOS this week: approach for teasing out archaic introgression in human genomes, immune transcription features in HCV infection, and more.
Stat News reports that Maryland is promoting itself to the biotech industry with a mobile billboard.